To develop biomarkers for an earlier diagnosis, and to find new therapeutic targets and strategies are critical challenges to cure Parkinson’s disease (PD). We identified, in a translational study, an unrivaled blood metabolic biomarker of PD, which indicates that pyruvate metabolism dysfunctions may be involved in PD pathogenesis. Here, we propose to investigate whether our biomarker is able to specifically detect PD since the prodromal phase, and to dissect the links between pyruvate metabolism defects and PD pathogenesis. To reach this goal, we will perform state-of-the-art metabolomics analyses in blood samples of prodromal patients and will combine behavioral, metabolic, molecular and neuroanatomical approaches in rat models of PD. This translational and multidisciplinary project is likely to provide a new diagnostic tool and therapeutic targets for a better management of PD.